AstraZeneca secured a fast approval of lung and breast cancer drugs with usually sluggish Japanese regulators, just months after scoring similar approvals in the West. The Japanese Ministry of ...

AstraZeneca and partner Daiichi’s drug, Datroway, was approved by the FDA for HR+ HER2- breast cancer in January and for EGFR-mutated non-small cell lung cancer (NSCLC) in June this year. Datroway ...

AstraZeneca’s efforts to move its top oncology drugs into earlier treatment settings have been lifted by positive data for Tagrisso and Imfinzi in lung cancer.

Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer By Annika Kim Constantino, CNBC • Published June 17, 2025 • Updated on June 17, 2025 at ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer By Annika Kim Constantino, CNBC • Published June 17, 2025 • Updated on June 17, 2025 at ...

AstraZeneca AZN announced that the FDA has expanded the label of its cancer drug Datroway for a second indication — non-small cell lung cancer (NSCLC). The drug has been developed in partnership ...

Companies such as AstraZeneca, Daiichi Sankyo, Pfizer, Merck and GSK are learning from previous setbacks in the ADC space to develop drugs that improve efficacy and reduce side effects.